Drug Profile
Research programme: topical anti-TNF-alpha therapeutics - York Pharma
Alternative Names: RPL-228Latest Information Update: 04 Apr 2011
Price :
$50
*
At a glance
- Originator York Pharma
- Class Small molecules
- Mechanism of Action Cytokine inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 13 Jun 2007 Preclinical trials in Psoriasis in United Kingdom (Topical)